Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue-associated market - research report released

companiesandmarkets.com

2009-10-23 22:33:04 - Stakeholder Opinions - Narcolepsy - Entry-point to a lucrative fatigue-associated market - a new market research report on companiesandmarkets.com

www.companiesandmarkets.com/Summary-Market-Report/stakeholder-op ..

Introduction

Narcolepsy is a chronic sleep disorder, which affects fewer than 500,000 sufferers across the seven major markets (7MM). The narcolepsy market value has grown considerably since 2004 to reach $230m in 2007 driven largely by the significant penetration of Provigil (modafinil; Cephalon) and Xyrem (sodium oxybate; Jazz Pharma) and the associated increase in the awareness of the disorder.

Scope

*Patient Patient potential including disease definition, etiology, prevalence, diagnosis, and treatment guideline review.

*Review of the key unmet needs in the treatment of narcolepsy as identified by key opinion leaders interviewed for the report.

*Analysis of narcolepsy market IMS sales data from 2004 to 2007 for major marketed narcolepsy drugs: Provigil and Xyrem.

*Pipeline analysis with detailed profile for Nuvigil (armodafinil, Cephalon) and the theory behind potential label expansions beyond narcolepsy.

Highlights

Although generic versions of Cephalon´s market leading treatment, Provigil (modafinil), are expected to launch in 2012, Datamonitor expects Cephalon to retain a significant position in the narcolepsy market by switching patients over from Provigil to its follow-up product, Nuvigil (armodafinil).

Despite Xyrem´s (sodium oxybate) proven efficacy and its broader narcolepsy coverage than Provigil, Xyrem´s sales continue to be limited because of its black box warning, restricted distribution and comparatively high price.

Targeting narcolepsy as a primary indication and then expanding Provigil´s label coverage to other sleep disorders has proven commercially successful for Cephalon. Datamonitor believes companies could take this strategy a step further by using narcolepsy as an entry point to access the broader fatigue- or sleepiness-associated market.

Reasons to Purchase

*Quantify the narcolepsy market value in the US, 5EU and Japan and identify the drivers and resistors in this market.

*Understand key opinion leader (KOL) views on topical issues in the current and future treatment of narcolepsy and associated disorders.

*Appreciate the potential of off-label prescribing and indication expansions for treatments possessing narcolepsy as the primary indication.